GeneOne Life Science, Inc. (KRX:011000)
South Korea · Delayed Price · Currency is KRW 2,670.00
+2,136.00 (400.00%)
Jul 22, 2026, 7:45 AM KST
GeneOne Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 12,365 | 23,045 | 35,720 | 40,203 | 48,718 | 38,700 |
Other Revenue | - | - | 0 | 0 | - | -0 |
| 12,365 | 23,045 | 35,720 | 40,203 | 48,718 | 38,700 | |
Revenue Growth | -64.38% | -35.48% | -11.15% | -17.48% | 25.89% | -6.75% |
Cost of Revenue | 29,285 | 38,261 | 46,687 | 48,088 | 39,541 | 30,058 |
Gross Profit | -16,920 | -15,217 | -10,967 | -7,885 | 9,177 | 8,642 |
Selling, General & Admin | 13,972 | 18,849 | 20,804 | 26,627 | 30,867 | 21,498 |
Research & Development | 1,270 | 1,929 | 3,556 | 7,043 | 12,147 | 11,441 |
Amortization of Goodwill & Intangibles | 186.89 | 283.89 | 196.54 | 287.07 | 182.57 | 156.36 |
Other Operating Expenses | 344.51 | 416.7 | 503.5 | 432.8 | 295.42 | 223.23 |
Operating Expenses | 25,069 | 28,820 | 32,072 | 40,483 | 49,376 | 36,170 |
Operating Income | -41,989 | -44,036 | -43,039 | -48,368 | -40,199 | -27,527 |
Interest Expense | -5,351 | -5,140 | -2,156 | -1,180 | -7,309 | -4,455 |
Interest & Investment Income | 439.61 | 186.58 | 125.18 | 518.68 | 6,216 | 1,538 |
Currency Exchange Gain (Loss) | 81.65 | 159.98 | -248.79 | 107.21 | 278.95 | 4,361 |
Other Non Operating Income (Expenses) | -2,215 | -3,151 | -3,433 | 3,569 | 2,958 | 9,638 |
EBT Excluding Unusual Items | -49,034 | -51,981 | -48,751 | -45,353 | -38,056 | -16,445 |
Gain (Loss) on Sale of Investments | -0.39 | - | -4.25 | 4.25 | - | - |
Gain (Loss) on Sale of Assets | -10.19 | 43.83 | 2.82 | 3.4 | 1.31 | -106.93 |
Asset Writedown | - | - | - | -32,309 | - | - |
Other Unusual Items | - | - | - | - | - | 1,018 |
Pretax Income | -49,044 | -51,937 | -48,753 | -77,655 | -38,054 | -15,534 |
Income Tax Expense | -108.82 | -86.36 | -216.19 | 113.45 | 95.79 | 353.75 |
Net Income | -48,936 | -51,851 | -48,537 | -77,768 | -38,150 | -15,888 |
Net Income to Common | -48,936 | -51,851 | -48,537 | -77,768 | -38,150 | -15,888 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 18 | 16 | 16 | 16 | 15 | 15 |
Shares Outstanding (Diluted) | 18 | 16 | 16 | 16 | 15 | 15 |
Shares Change | -61.22% | 3.82% | 2.17% | 0.34% | 4.37% | 22.98% |
EPS (Basic) | -2698.70 | -3143.66 | -3055.00 | -5001.17 | -2461.75 | -1070.01 |
EPS (Diluted) | -2698.70 | -3143.66 | -3055.00 | -5001.17 | -2461.75 | -1070.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13,293 | -16,565 | -19,356 | -27,345 | -69,419 | -87,291 |
Free Cash Flow Per Share | -733.06 | -1004.30 | -1218.29 | -1758.52 | -4479.48 | -5878.87 |
Gross Margin | -136.84% | -66.03% | -30.70% | -19.61% | 18.84% | 22.33% |
Operating Margin | -339.57% | -191.09% | -120.49% | -120.31% | -82.51% | -71.13% |
Profit Margin | -395.75% | -225.00% | -135.88% | -193.44% | -78.31% | -41.05% |
Free Cash Flow Margin | -107.50% | -71.88% | -54.19% | -68.02% | -142.49% | -225.56% |
EBITDA | -24,873 | -25,840 | -25,078 | -35,592 | -34,776 | -22,877 |
EBITDA Margin | -201.15% | -112.13% | -70.21% | -88.53% | -71.38% | -59.11% |
D&A For EBITDA | 17,116 | 18,196 | 17,961 | 12,776 | 5,424 | 4,650 |
EBIT | -41,989 | -44,036 | -43,039 | -48,368 | -40,199 | -27,527 |
EBIT Margin | - | -191.09% | -120.49% | -120.31% | -82.51% | -71.13% |
Advertising Expenses | - | 320.19 | 381.32 | 196.96 | 341.71 | 194.45 |